DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML

Summary

For several years, the effective standard induction chemotherapy for AML has been limited to the association of anthracycline and aracytine. GO is the first effective targeted antibody used in leukemia patients. In a previous study, we showed efficacy and safety of fractionated doses of GO used as a single agent for treatment of adult AML patients in first relapse. In the present study the possibility of combining fractionated doses of GO to escalated doses of a 3+7 regimen old is studied in relapsed AML patients \> 50 and \<70 years.

Timeline

Start

2006-06

Primary completion

2007-09

Completion

2011-01

Drugs

Indications